A
Akarna Therapeutics
At Akarna, our mission is to develop best-in-class treatments for NASH and other chronic liver diseases
About Akarna Therapeutics
Akarna Therapeutics is a biotech startup dedicated to developing innovative treatments for Non-Alcoholic Steatohepatitis (NASH) and other chronic liver diseases. NASH is a severe form of fatty liver disease closely linked to diabetes and obesity, affecting around 30 million people with no approved therapies currently available. This condition is becoming increasingly common and poses significant health risks.
Akarna's primary focus is on creating drugs that activate the Farnesoid X Receptor (FXR). FXR is a crucial regulator of metabolic, inflammatory, and fibrosis pathways in the liver. By targeting FXR, Akarna aims to address the underlying causes of NASH, offering a potential breakthrough in treatment where none currently exists.
The company operates in the biopharmaceutical market, specifically targeting liver diseases. Its clients include healthcare providers, medical researchers, and ultimately, patients suffering from NASH and related conditions. Akarna's business model revolves around research and development (R&D) of new drugs, followed by clinical trials, regulatory approval, and eventual commercialization. Revenue is generated through the sale of these approved drugs, partnerships with larger pharmaceutical companies, and potentially through licensing agreements.
Akarna's commitment to finding a cure for NASH positions it as a key player in the fight against this growing health issue. By focusing on FXR activators, the company aims to bring effective and much-needed treatments to market, improving the lives of millions of patients.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2016 | $0 | — | Allergan | — |
| SERIES B✓Equity / VC | Feb 2016 | $15M | $60M | Third Point Ventures · Forbion Capital Partners · New Science Ventures | — |
Growth signals
Latest recorded traffic for Akarna Therapeutics is 0 monthly website visits, down 100% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Akarna Therapeutics in the Cambridge ecosystem
The Akarna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Forbion Capital Partners
Third Point Ventures
New Science Ventures
Other known investors1 additional known investor
Allergan
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Akarna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Akarna Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









